| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 23.1 | 23.4 |
| Gross profit | 19.5 | 19.2 |
| Net income | -3.3 | -3.5 |
| EPS (diluted, $ a share) | $-0.10 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -1.1% |
|---|---|
| Gross margin | 84.3% |
| Operating margin | -9.0% |
10-Q filed with the SEC, NASDAQ: NPCE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
NeuroPace Inc: key numbers
- Share price
- $7.97Close, Nov 16
- Market cap
- $275M
- Shares outstanding
- 34.45MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from NeuroPace Inc
All →NeuroPace Earnings Call: Key Takeaways
NeuroPace reported a disappointing Q3 with revenue declining 1.1% year-over-year, leading to a significant full-year guidance cut due to salesforce disruption and operational issues at major accounts.
- Call
- Nov 12, 2026, 4:30 PM ET
NeuroPace Financial Results
NeuroPace reported Q3 2026 total revenue of $23.1 million, missing internal expectations due to commercial execution issues and field organization disruption. The company revised its full-year 2026 revenue guidance downward to $91-$92 million while advancing its innovation pipeline, including an FDA submission for NeuroPace Remote Care.
- Term
- Q3 2026
“Third-quarter revenue was below our expectations, and we have taken and are taking action to improve commercial execution and return the business to historical growth rates. The shortfall was concentrated in several of our largest accounts and reflected isolated account-level issues and changes to our field organization that created more disruption than anticipated.”
Joel Becker, President and Chief Executive Officer of NeuroPace
“Our innovation pipeline represents one of the most significant opportunities ahead for NeuroPace, combining potential indication expansion with capabilities that can make RNS therapy more accessible, efficient and personalized.”
Joel Becker, President and Chief Executive Officer of NeuroPace